Peptides for Erectile Dysfunction: Do They Work and Are They Legal in the UK?

Several peptides are promoted online as treatments for erectile dysfunction, but none are licensed by the MHRA for this use in the UK, none are recommended by NICE, and the clinical evidence for most of them is thin at best.

The peptides most commonly marketed for ED#

Three names come up repeatedly: Melanotan II (MT-II), PT-141 (also called bremelanotide), and BPC-157.

Melanotan II acts on melanocortin receptors in the brain, particularly MC3R and MC4R, which play a role in sexual arousal. Early trials in the late 1990s and early 2000s did show that MT-II could produce erections in some men. A 1998 study of 10 men with psychogenic ED found that 8 of the 10 had erectile responses after a subcutaneous injection of 0.025 mg/kg, though it should be noted the trial had significant methodological limitations beyond its small sample size, including a crossover design and no placebo-controlled arm for the primary endpoint. A 2000 study in men with organic ED also reported improved erections, though the sample sizes were small and the results were inconsistent. These are proof-of-concept findings, not the basis for clinical use.

Side effects in those trials were notable: nausea, flushing, yawning, and spontaneous erections (including priapism — a prolonged erection lasting more than four hours that is a urological emergency requiring immediate attendance at an emergency department) were all reported. Longer-term, MT-II causes hyperpigmentation of moles and skin, and there are theoretical cardiovascular risks from its effects on blood pressure.

PT-141 (bremelanotide) is a derivative of MT-II. It received FDA approval in the US in 2019, but specifically for hypoactive sexual desire disorder in premenopausal women, not for erectile dysfunction in men. That approval does not extend to the UK, and bremelanotide has no MHRA marketing authorisation for any indication. The mechanism is central (brain-based) rather than vascular, which is why it was investigated, but the approved use and the unlicensed male ED use are entirely separate things.

BPC-157 is a synthetic peptide with proposed tissue-healing properties. There is essentially no human trial data for BPC-157 in any condition, let alone ED. Animal studies have shown some interesting effects on blood vessels and tissue repair, but animal findings frequently do not translate to humans. It is not authorised for human use anywhere.

The UK legal position#

None of these peptides hold a UK marketing authorisation. Under UK law, supplying an unlicensed medicine without appropriate authorisation is illegal. Purchasing peptides online for personal use is not straightforwardly legal under the Human Medicines Regulations 2012; MHRA enforcement discretion is not the same as legality. Beyond the legal question, the risk is also clinical: products sold as "research peptides" online have no quality control. Purity, dosing accuracy, and sterility are all unverified, which matters a great deal when injecting something directly under the skin.

The MHRA has taken enforcement action against suppliers of unlicensed medicines and has issued warnings about products sold outside the licensed supply chain. If you experience side effects from an unlicensed product, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Why some men look for alternatives to standard ED treatments#

This is worth addressing honestly. Some men do not respond adequately to PDE5 inhibitors like sildenafil or tadalafil. A key absolute contraindication for all PDE5 inhibitors is concurrent use of nitrate medication (used for chest pain), where the combination causes a dangerous drop in blood pressure — men in this group cannot safely take any PDE5 inhibitor. Others experience side effects like headaches, flushing, or visual disturbances that make continued use difficult.

For men in this group, the answer is not unregulated peptides. Legitimate options include dose adjustment, switching between PDE5 inhibitors (they are not all identical in their profile), referral to a urology or sexual medicine specialist, vacuum erection devices, or in some cases penile injections such as alprostadil, which is licensed in the UK. A GP can refer for specialist review if standard treatments have not worked.

It is also worth knowing that some men with specific conditions are entitled to NHS prescriptions for sildenafil at no cost. These conditions include diabetes, multiple sclerosis, Parkinson's disease, kidney failure, spinal cord injury, single-gene neurological conditions, severe pelvic injury, and prostate cancer treatment side effects, among others. Eligibility depends on having the relevant condition documented and being properly assessed — a GP can advise whether you qualify. Many men are not aware of this entitlement.

If you are researching ED treatments and want to understand your licensed options, the Totiva ED treatment guide covers what is available, how each medicine works, and how to access treatment safely. For a broader look at the evidence behind individual medicines, the tadalafil dosage guide is a useful starting point.